In this study, ctDNA successfully identified Anaplastic Lymphoma Kinase (ALK) rearrangements in treatment-naive NSCLC patients, enabling the initiation of targeted therapy and achieving response rates comparable to tissue-based testing [132]. Here, ALK is linked to non-small cell lung carcinoma.